Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disrupted in renal carcinoma 1 (DIRC1)
- Target
- DIRC1
- Molecular classification
- Long non-coding RNA, lncRNA
01
Overview
Disrupted in renal carcinoma 1 (DIRC1), also known as Disrupted in renal cancer protein 1, is a long non-coding RNA gene originally found disrupted in families with inherited renal cell carcinoma due to a chromosomal translocation t(2;3)(q33;q21). DIRC1 does not encode a functional protein; rather, it acts as an RNA regulator. Its aberrant expression is associated with cancer susceptibility and progression, including familial renal cell carcinoma and stomach adenocarcinoma, where high DIRC1 expression correlates with worse prognosis, more advanced tumor stage, and increased immune cell infiltration. DIRC1 is considered a novel prognostic biomarker for several cancers, but there are no drugs or therapies directly targeting it, and its precise molecular mechanisms remain incompletely understood.
- Other names
- Disrupted in renal cancer protein 1DIRC1Disrupted in renal cancer protein
02
Biological functions
Regulation of gene expression (via chromatin modification, transcriptional and post-transcriptional mechanisms)Potential involvement in cell proliferation, cell cycle regulation (G2/M checkpoint, E2F signaling, MYC targets), immune cell infiltration, and epithelial-mesenchymal transition in cancer
03
Disease associations
Familial renal cell carcinomaSporadic renal cell carcinomaStomach adenocarcinomaPrognostic biomarker in stomach cancerPotential oncogene in gastric cancer
04
Biomarkers
DIRC1 RNA expression (biomarker for poor prognosis in stomach adenocarcinoma/gastric cancer and for select subtypes of renal cancer)
Beyond the preview
Go deeper on Disrupted in renal carcinoma 1 (DIRC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Disrupted in renal carcinoma 1 (DIRC1).